AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02497079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nested PCR for formalin-fixed tissues
Description: For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
Study NCT02497079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nested PCR for fresh tissues
Description: For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
Study NCT02497079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time PCR for fresh tissues
Description: For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
Study NCT02212106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)
Description: Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
Study NCT02212106 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Quadrivalent Influenza Virus Vaccine
Description: Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
Study NCT00999284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK200775
Description: Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
Study NCT02556736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RST-001
Description: RST-001 is a gene therapeutic delivered by intravitreal injection
Study NCT02774746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35-week delivery
Description: Induction at 35 weeks gestational age
Study NCT02774746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 38-week delivery
Description: Observation to spontaneous delivery or induction at 38 weeks gestational age
Study NCT03594435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: targets neurotrophin signaling and neuroimmune function
Study NCT03594435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: matched to active drug, ibudilast
Study NCT02585583 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Thalamotomy
Description: VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
Study NCT04060030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin Calcium
Description: Liquid leucovorin calcium dosed by weight
Study NCT04060030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04118933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 240mg, Q3W
Study NCT02129829 — intervention group
Intervention type: DRUG
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil 245 mg once daily
Study NCT00857415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
Study NCT06185127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
Study NCT06185127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
Study NCT06185127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.
Study NCT06185127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
Study NCT03024697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pectoral Plane Block
Study NCT03024697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anaesthetic Wound Infusion Catheter
Description: Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
Study NCT03839082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care then FitBit
Description: Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
Study NCT03839082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care then FitBit
Description: Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
Study NCT03839082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FitBit then Usual Care
Description: Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
Study NCT03861728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.01% Hypochlorous acid
Description: Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
Study NCT03839082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FitBit then Usual Care
Description: Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
Study NCT03275792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5-0.9%NS
Description: Admission for intravascular volume expansion
Study NCT03275792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine home oral rehydration
Description: Routine oral fluids as is given at home to all children with acute diarrheal disease
Study NCT01756053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-089
Description: Selective neuronal nicotinic receptor agonist.
Study NCT01756053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules supplied by study drug supplier.
Study NCT03506932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Untreated
Description: Bread made with 20% yellow pea flour that was untreated.
Study NCT03506932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heat treated with 0% moisture
Description: Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
Study NCT03506932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heat treated with 10% moisture
Description: Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
Study NCT03506932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat
Description: Bread made with 100% wheat
Study NCT01230710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib was supplied as tablets.
Study NCT02946983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: Intragastric administration of fructose (25g dissolved in 250ml distilled water)
Study NCT03861728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be used four times a day to the affected eye for 2 weeks
Study NCT04504773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Participants will receive a single session of virtual reality exposure therapy that targets the participant's specific phobia stimuli.
Study NCT01079598 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RF Ablation (ClosureRFS Stylet)
Description: Bipolar energy radiofrequency ablation with RFS stylet
Study NCT01288638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse-based diet
Description: The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
Study NCT01288638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TLC diet
Description: Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
Study NCT00766857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
Study NCT04264689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus anterior block
Description: ultrasound guided block
Study NCT04264689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: thoracic epidural
Study NCT04264689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block
Description: ultrasound guided block
Study NCT03063203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: * After 2 cycles, patients with progressive disease or relapse (a clear progression with at least >20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~* Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~* Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~* Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference.
Study NCT03063203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy/aspirate
Description: * Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~* Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~* Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician
Study NCT03063203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
Study NCT03063203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: * Optional but if refuse skin biopsy then participant can provided buccal swab~* There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~* If WBC at time of enrollment is >30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter
Study NCT03063203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal swab
Description: -Baseline (if skin biopsy declined) and Cycle 2 Day 28
Study NCT04025710 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BIOMONITOR III and BIOMONITOR IIIm
Description: * Insertion of BIOMONITOR III or BIOMONITOR IIIm~* three scheduled in-office follow-ups~* 48-hour Holter ECG
Study NCT02089854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene; Anastrozole
Description: Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
Study NCT02801305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Gel 2%
Description: This a topical agent which will be applied on digital ulcers by scleroderma patients.
Study NCT00766857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
Study NCT02801305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin Ointment 2%
Description: This a topical agent which will be applied on digital ulcers by scleroderma patients.
Study NCT02801305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: This is used as the topical placebo agent.
Study NCT00876746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular vs. Infraclavicular ropivicaine infusion
Description: Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
Study NCT04045119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Moisturizer
Description: The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
Study NCT03720340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Interleukin-11
Description: Recombinant Human Interleukin-11 was administed through respiratory tract.
Study NCT03720340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline was administed through respiratory tract
Study NCT03720340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline was administed through respiratory tract
Study NCT02374957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: 100 mg twice daily for 90 days
Study NCT03751878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of reporting inconsistencies
Description: 1. The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~2. DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~3. This editor will include the report in the letter to authors alongside the standard peer review reports.
Study NCT03751878 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Peer Review.
Description: Manuscripts will undergo the usual peer review process.
Study NCT03532178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline
Description: The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period.
Study NCT03532178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;
Description: The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period.
Study NCT02774252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
Study NCT02228278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals.
Study NCT02228278 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group B
Description: Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals.
Study NCT02342561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ioban 2 incision drape, 3M
Description: The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
Study NCT01729598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: generic valproic acid tablets packaged in placebo-matched capsules.
Study NCT01729598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule without active study medication in identical capsules as experimental medicine.
Study NCT03014219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Only 1 arm: treatment with MSC-AFP
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
Study NCT02583789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral treprostinil
Description: Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
Study NCT02583789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral treprostinil
Description: Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
Study NCT02583789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase